ANVS Logo

Annovis Bio Inc (ANVS) Stock Forecast & Price Prediction

Live ANVS Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Biotechnology

$2.74

-0.20 (-6.80%)

12 Month Price Forecast For ANVS

$2.74
Current Price
$53.59M
Market Cap
6 Ratings
Buy 5
Hold 1
Sell 0
Wall St Analyst Ratings

Distance to ANVS Price Forecasts

+2,527.7%
To High Target of $72.00
+848.9%
To Median Target of $26.00
+666.4%
To Low Target of $21.00

ANVS Price Momentum

-12.7%
1 Week Change
-44.0%
1 Month Change
-75.0%
1 Year Change
-45.5%
Year-to-Date Change
-86.3%
From 52W High of $20.00
+5.8%
From 52W Low of $2.59

๐Ÿค” Considering Annovis Bio (ANVS)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 3:27 AM UTC

ANVS Analyst Ratings & Price Targets

Based on our analysis of 8 Wall Street analysts, ANVS has a bullish consensus with a median price target of $26.00 (ranging from $21.00 to $72.00). Currently trading at $2.74, the median forecast implies a 848.9% upside. This outlook is supported by 5 Buy, 1 Hold, and 0 Sell ratings.

Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 666.4% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

ANVS Analyst Consensus

5
Buy
1
Hold
0
Sell

ANVS Price Target Range

Low
$21.00
Average
$26.00
High
$72.00
Current: $2.74

Latest ANVS Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for ANVS.

Date Firm Analyst Rating Change Price Target
Feb 10, 2025 D. Boral Capital Jason Kolbert Hold Downgrade $0.00
Nov 11, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $30.00
Nov 11, 2024 D. Boral Capital Jason Kolbert Buy Maintains $21.00
Oct 25, 2024 Maxim Group Jason McCarthy Buy Upgrade $25.00
Oct 16, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $30.00
Oct 15, 2024 EF Hutton Jason Kolbert Buy Maintains $21.00
Oct 1, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $30.00
Aug 15, 2024 EF Hutton Jason Kolbert Buy Maintains $21.00
Aug 15, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $30.00
Aug 13, 2024 EF Hutton Jason Kolbert Buy Initiates $21.00
Jul 17, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $30.00
Jul 11, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $30.00
Jul 2, 2024 Rodman & Renshaw Elemer Piros Buy Reiterates $67.00
Jun 12, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $23.00
Jun 4, 2024 Rodman & Renshaw Buy Initiates $67.00
May 13, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $23.00
Apr 30, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $30.00
Apr 30, 2024 Canaccord Genuity Sumant Kulkarni Buy Maintains $26.00
Apr 2, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Maintains $30.00
Mar 21, 2024 HC Wainwright & Co. Raghuram Selvaraju Buy Reiterates $30.00

Stocks Similar to Annovis Bio Inc

The following stocks are similar to Annovis Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Annovis Bio Inc (ANVS) Financial Data

Annovis Bio Inc has a market capitalization of $53.59M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -596.7%.

Valuation Metrics

Market Cap $53.59M
Enterprise Value $27.93M
P/E Ratio -0.4x
PEG Ratio -1.5x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin 0.0%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +33.4%
Current Ratio 2.7x
Debt/Equity 0.0x
ROE -596.7%
ROA -154.6%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Annovis Bio Inc logo

Annovis Bio Inc (ANVS) Company Overview

About Annovis Bio Inc

What They Do

Develops drugs for neurodegenerative diseases.

Business Model

Annovis Bio, Inc. operates as a clinical stage drug platform company, focusing on the development of innovative therapies for neurodegeneration. The company generates value through the advancement of its drug candidates, primarily Buntanetap, ANVS405, and ANVS301, which are aimed at treating conditions like Alzheimer's and Parkinson's disease. Revenue will be generated through potential future sales of these drugs upon successful clinical trials and subsequent market approval.

Additional Information

Incorporated in 2008 and headquartered in Malvern, Pennsylvania, Annovis Bio has completed significant clinical trials and is actively pursuing multiple drug candidates in various stages of development. Their focus on neurodegenerative diseases addresses a critical area of unmet medical need, potentially positioning them for lucrative partnerships or acquisitions in the pharmaceutical industry.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

6

CEO

Dr. Maria L. Maccecchini Ph.D.

Country

United States

IPO Year

2020

Annovis Bio Inc (ANVS) Latest News & Analysis

ANVS stock latest news image
Quick Summary

Annovis Bio Inc. (NYSE: ANVS) has initiated a pivotal Phase 3 study for its drug buntanetap in early Alzheimer's disease, with the first two patients enrolled.

Why It Matters

The initiation of a pivotal Phase 3 study for buntanetap in early Alzheimer's could lead to significant advancements in treatment, impacting Annovis Bio's market potential and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
ANVS stock latest news image
Quick Summary

Annovis Bio Inc. (NYSE: ANVS) announced CEO Maria Maccecchini will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, focusing on therapies for Alzheimer's and Parkinson's diseases.

Why It Matters

Annovis Bio's CEO presenting at a major healthcare conference highlights the company's visibility and potential growth in the neurodegenerative disease market, crucial for investor sentiment and stock performance.

Source: GlobeNewsWire
Market Sentiment: Neutral
ANVS stock latest news image
Quick Summary

Annovis Bio, Inc. announced a public offering of 5.25 million shares and warrants at $4.00 each, aiming for $21 million in gross proceeds. The offering closes on February 4, 2025.

Why It Matters

Annovis Bio's public offering indicates financial strategy and potential growth, raising $21M for R&D in neurodegenerative diseases, which could impact stock performance and investor confidence.

Source: GlobeNewsWire
Market Sentiment: Neutral
ANVS stock latest news image
Quick Summary

Annovis Bio, Inc. closed a public offering of 5.25 million shares and warrants at $4.00 each, raising $21 million. Warrants are exercisable at $5.00 for five years.

Why It Matters

Annovis Bio's $21 million raise through a public offering signals confidence in its pipeline for neurodegenerative disease therapies, potentially impacting stock value and investor interest.

Source: GlobeNewsWire
Market Sentiment: Neutral
ANVS stock latest news image
Quick Summary

Annovis Bio, Inc. plans to launch an underwritten public offering of common stock and warrants, with all shares sold by the company.

Why It Matters

Annovis Bio's stock offering may dilute existing shares, impacting current shareholders' value. It signals the company's need for capital, influencing investor sentiment and stock price.

Source: GlobeNewsWire
Market Sentiment: Neutral
ANVS stock latest news image
Quick Summary

Annovis Bio Inc. (NYSE: ANVS) announced it received a U.S. patent for using buntanetap to treat and prevent acute brain or nerve injuries, enhancing its portfolio in neurodegenerative therapies.

Why It Matters

The patent grants Annovis Bio exclusive rights to a potentially groundbreaking treatment for brain injuries, which could enhance its market position and drive stock value.

Source: GlobeNewsWire
Market Sentiment: Neutral

Frequently Asked Questions About ANVS Stock

What is Annovis Bio Inc's (ANVS) stock forecast for 2025?

Based on our analysis of 8 Wall Street analysts, Annovis Bio Inc (ANVS) has a median price target of $26.00. The highest price target is $72.00 and the lowest is $21.00.

Is ANVS stock a good investment in 2025?

According to current analyst ratings, ANVS has 5 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.74. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for ANVS stock?

Wall Street analysts predict ANVS stock could reach $26.00 in the next 12 months. This represents a 848.9% increase from the current price of $2.74. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Annovis Bio Inc's business model?

Annovis Bio, Inc. operates as a clinical stage drug platform company, focusing on the development of innovative therapies for neurodegeneration. The company generates value through the advancement of its drug candidates, primarily Buntanetap, ANVS405, and ANVS301, which are aimed at treating conditions like Alzheimer's and Parkinson's disease. Revenue will be generated through potential future sales of these drugs upon successful clinical trials and subsequent market approval.

What is the highest forecasted price for ANVS Annovis Bio Inc?

The highest price target for ANVS is $72.00 from at , which represents a 2,527.7% increase from the current price of $2.74.

What is the lowest forecasted price for ANVS Annovis Bio Inc?

The lowest price target for ANVS is $21.00 from Jason Kolbert at D. Boral Capital, which represents a 666.4% increase from the current price of $2.74.

What is the overall ANVS consensus from analysts for Annovis Bio Inc?

The overall analyst consensus for ANVS is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $26.00.

How accurate are ANVS stock price projections?

Stock price projections, including those for Annovis Bio Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.